Caplacizumab: frequent local skin reactions
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04260-7
Abstract: Dear Editor, Caplacizumab (Cablivi®) is a novel anti-von Willebrand factor (vWF) nanobody approved for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) [1]. A single-dose (10 mg) caplacizumab is given intravenously before starting plasma exchange… read more here.
Keywords: local skin; treatment; skin reactions; caplacizumab ... See more keywords
Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1992413
Abstract: AIM The aim of this study was to model the financial impact of caplacizumab with therapeutic plasma exchange (TPE) + immunosuppression for patients experiencing an acute acquired thrombotic thrombocytopenic purpura (aTTP) episode versus TPE + immunosuppression, from… read more here.
Keywords: impact caplacizumab; hospital; caplacizumab; tpe immunosuppression ... See more keywords
Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2202850
Abstract: ABSTRACT Background Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy. Several studies have demonstrated the efficacy of caplacizumab in iTTP. However, the effect on different populations remains controversial. Therefore, we performed a… read more here.
Keywords: safety; meta analysis; review; thrombotic thrombocytopenic ... See more keywords
P0202FIRST REAL-LIFE DATA OF PATIENTS TREATED FOR THROMBOTIC THROMBOCYTOPENIC PURPURA FROM THE FRENCH THROMBOTIC MICROANGIOPATHIES NETWORK
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p0202
Abstract: Caplacizumab, a bivalent Nanobody, targets the A1 domain of von Willebrand Factor, inhibiting the interaction between ultra-large vWF and platelets in the treament of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Phase 3 HERCULES… read more here.
Keywords: attp; caplacizumab; treatment; platelet count ... See more keywords
Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16977
Abstract: Thrombotic Thrombocytopenic Purpura (TTP) is caused by reduced activity of von Willebrand factor (VWF) cleaving protease ADAMTS13 which causes the formation of blood clots in small blood vessels throughout the body. TTP presents as a… read more here.
Keywords: treatment; plasma exchange; ttp; caplacizumab ... See more keywords
Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18080
Abstract: Acquired immune thrombotic thrombocytopenic purpura (iTTP) is a rare disease with a poor prognosis if undiagnosed. It is caused by autoantibody production to the von Willebrand factor (VWF) cleaving protease, A disintegrin and metalloproteinase with… read more here.
Keywords: immune thrombotic; vwf; factor; activity ... See more keywords
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2020001973
Abstract: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX)… read more here.
Keywords: real world; treatment; acquired thrombotic; caplacizumab ... See more keywords
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2020001987
Abstract: Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of… read more here.
Keywords: adamts13 activities; treatment; caplacizumab treatment; caplacizumab ... See more keywords
Caplacizumab as frontline therapy in addition to standard treatment in iTTP
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022009448
Abstract: We read with interest the meta-analysis performed by Djulbegovic et al about the use of caplacizumab as a treatment for patients with immune thrombotic thrombocytopenic purpura (iTTP). 1 We respectfully disagree with some of the… read more here.
Keywords: addition; ittp; caplacizumab frontline; standard ... See more keywords